1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/ciz398" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/ciz398</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
S40-S47
Volume
69
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
Publisher
An entity responsible for making the resource available
Clinical Infectious Diseases: An Official Publication Of The Infectious Diseases Society Of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
2019-08
Subject
The topic of the resource
COMMUNICABLE diseases; community-acquired bacterial pneumonia; COMMUNITY-acquired pneumonia; DENTAL discoloration; omadacycline; PATIENT safety; safety; skin and skin structure infections; SKIN diseases; TEETH abnormalities; TETRACYCLINE; THERAPEUTIC use
Creator
An entity primarily responsible for making the resource
Opal Steven; File Thomas M; van der Poll Tom; Tzanis Evan; Chitra Surya; McGovern Paul C
Description
An account of the resource
Omadacycline is a semisynthetic tetracycline antibiotic. Phase III clinical trial results have shown that omadacycline has an acceptable safety profile in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Similar to most tetracyclines, transient nausea and vomiting and low-magnitude increases in liver aminotransferases were the most frequent treatment-emergent adverse events in phase III studies but were not treatment limiting. Package insert warnings and precautions for omadacycline include tooth discoloration; enamel hypoplasia; inhibition of bone growth following use in late pregnancy, infancy, or childhood up to 8 years of age; an imbalance in mortality (2%, compared with 1% in moxifloxacin-treated patients) was observed in the phase III study in patients with community-acquired bacterial pneumonia. Omadacycline has no effect on the QT interval, and its affinity for muscarinic M2 receptors resulted in transient heart rate increases following dosing.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/ciz398" target="_blank" rel="noreferrer noopener">10.1093/cid/ciz398</a>
2019
Chitra Surya
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Communicable Diseases
community-acquired bacterial pneumonia
Community-acquired pneumonia
DENTAL discoloration
Department of Internal Medicine
File Thomas M
McGovern Paul C
NEOMED College of Medicine
omadacycline
Opal Steven
Patient Safety
Safety
September 2019 Update
skin and skin structure infections
Skin Diseases
TEETH abnormalities
tetracycline
THERAPEUTIC use
Tzanis Evan
van der Poll Tom